Breast

Papers
(The H4-Index of Breast is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Current and future burden of breast cancer: Global statistics for 2020 and 2040537
Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic159
The requirements of a specialist breast centre104
Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer81
Global guidelines for breast cancer screening: A systematic review64
Reduced symptom burden with the support of an interactive app during neoadjuvant chemotherapy for breast cancer – A randomized controlled trial62
Changes in breast cancer management during the Corona Virus Disease 19 pandemic: An international survey of the European Breast Cancer Research Association of Surgical Trialists (EUBREAST)57
Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: A systematic review50
Epidemiology of male breast cancer50
Effect of implementing digital breast tomosynthesis (DBT) instead of mammography on population screening outcomes including interval cancer rates: Results of the Trento DBT pilot evaluation48
Diagnostic accuracy of contrast-enhanced spectral mammography for breast lesions: A systematic review and meta-analysis46
The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A qualitative systematic review and thematic synthesis42
Using artificial intelligence to analyse and teach communication in healthcare41
Effects of the COVID-19 pandemic on breast cancer screening in Taiwan41
Dissecting the biological heterogeneity of HER2-positive breast cancer39
Global challenges in breast cancer detection and treatment38
A systematic review and meta-analysis of clinician-reported versus patient-reported outcomes of radiation dermatitis38
Clinical utility of tumour marker velocity of cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) in breast cancer surveillance34
Breast cancer surgery with augmented reality33
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data fr32
Mammographic breast density and the risk of breast cancer: A systematic review and meta-analysis31
Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy31
The impact of young age at diagnosis (age <40 years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis30
Occult breast cancer: Where are we at?30
Breast malignancy in female-to-male transsexuals: systematic review, case report, and recommendations for screening29
Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer29
The emerging role of BET inhibitors in breast cancer29
Clinical utility of the 21-gene assay in predicting response to neoadjuvant endocrine therapy in breast cancer: A systematic review and meta-analysis28
0.069639921188354